Manages alternative asset portfolios across credit, real estate, and specialty finance. Operates Great Elm Capital Corp., a publicly-traded business development company. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 57% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 26.1× for every dollar of annual revenue.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 57% a year on average.
Sales run at $27.8M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 65 buys and 4 sells. Management buying with its own money is usually read as a good sign.
A loss of $35.4M against $27.8M in annual sales.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution.